Scheme 1. Schematic of a Gd(iii)–Pt(iv) theranostic agent. In the oxidizing extracellular environment, the agent remains in the Pt(iv) oxidation state.¹⁵ Upon entering the cell, the agent is reduced to Pt(ii), simultaneously releasing the therapeutic Pt(ii) drug and a Gd(iii) MR contrast agent.